Immuno-Oncology Co-culture Assays
Oncology (Immunotherapy)
Key Facts
About Okomera
Okomera is an innovative biotech company building a next-generation, automated platform for organoid-based drug discovery and personalized medicine. Its core technology leverages microfluidic chips to generate and screen thousands of patient-derived 3D tumor spheroids against hundreds of drug conditions (chemotherapy, immunotherapy, cell therapy) in a highly miniaturized and automated workflow, significantly reducing sample requirements and turnaround time compared to conventional methods. By combining high-throughput biology with AI-driven analysis, Okomera aims to improve the predictability of preclinical studies and enable scalable, data-rich applications such as CRISPR screening, T-cell potency testing, and combinatorial drug discovery. The company is positioned as a platform technology provider serving the broader oncology research and drug development market.
View full company profile